Monogram Technologies to Host Second Quarter 2024 Business Update Conference Call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time

August 1, 2024 11:15 AM

AUSTIN, TX / ACCESSWIRE / August 1, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a business update conference call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time in conjunction with its reported financial results for the second quarter ended June 30, 2024 and to discuss key milestones....

Read more

Zoelife Psychiatric Services Receives Prestigious Accreditation for Outpatient Treatment for Adults, Children and Adolescents

August 1, 2024 10:00 AM

FRANKFORT, IL / ACCESSWIRE / August 1, 2024 / Zoelife Psychiatric Services is proud to announce that it has earned a prestigious Three-Year Accreditation from the Commission on Accreditation of Rehabilitation Facilities (CARF) for its Outpatient treatment mental health programs for Adults, Children, and Adolescents located in Frankfort and Cresthill, Illinois. This esteemed recognition represents the highest level of accreditation that CARF can...

Read more

Quest Diagnostics Named a "Best Place to Work for Disability Inclusion" for Seventh Straight Year

August 1, 2024 10:00 AM

Quest Diagnostics (NYSE:DGX), a leading provider of diagnostic information services, announced it has been named to the 2024 Disability Equality Index® Best Places to Work for Disability Inclusion by Disability: IN and the American Association of People with Disabilities (AAPD).The announcement marks the seventh consecutive year that Quest has been recognized by the Disability Equality Index®. The company achieved a top score of 100, improving...

Read more

1upHealth Launches Customer Advisory Board to Advance Industry-Wide Interoperability and Fuel Technological Innovation

August 1, 2024 9:03 AM

1upHealth, the leading health data management platform provider for claims and clinical data interoperability, today announced it has formed a Customer Advisory Board (CAB) to leverage the unique expertise of its client base and drive company and industry innovation. The CAB showcases a broad collective of executives from leading health plans such as CVS/Aetna, Mass General Brigham Health Plan, AIDS Healthcare Foundation (AHF), Cigna Healthcare,...

Read more

Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting

August 1, 2024 9:00 AM

SAN FRANCISCO, CA / ACCESSWIRE / August 1, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") family company Napo Pharmaceuticals ("Napo") today announced that the results of two independent investigator-initiated studies of crofelemer, Napo's novel, plant-based oral prescription drug, showed a benefit in patients with chronic refractory diarrhea and have been accepted for poster presentations at the American College of Gastroenterology Annual...

Read more

Animal Surgical Center Proudly Announces AAHA Accreditation: Leading the Way in Veterinary Excellence

August 1, 2024 9:00 AM

Animal Surgical Center Earns Coveted AAHA Accreditation, Demonstrating Unwavering Commitment to Excellence in Veterinary CareOCEANSIDE, NY / ACCESSWIRE / August 1, 2024 / Animal Surgical Center, a premier multi-disciplinary veterinary practice located in Oceanside, New York, is thrilled to announce that they have achieved accreditation from the prestigious American Animal Hospital Association (AAHA). This accolade places them among only 15% of...

Read more

Village Savings and Loan Associations, With Kal Lakew and Emily Janoch

August 1, 2024 8:15 AM

Podcast Interview exploring the balance between designing for evidence and building for adaptation.NORTHAMPTON, MA / ACCESSWIRE / August 1, 2024 / CAREOriginally published on Business Fights PovertyWhat are Village Savings and Loan Associations (VSLAs) and why can they be transformative for communities, particularly for women? Social Impact Pioneers Kalkidan (Kal) Lakew and Emily Janoch from the international NGO, CARE, explore how VSLAs...

Read more

CBD Life Sciences, Inc. (CBDL) Signs MOU With Large Mushroom Supplement Company

August 1, 2024 8:00 AM

SCOTTSDALE, AZ / ACCESSWIRE / August 1, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), including its wholly-owned subsidiary, The CBD Vault Inc., a leading innovator in the CBD industry, has announced that it's signed a MOU (Memorandum of understanding) with a mushroom supplement company. This company will work hand in hand with our vision as were able to expand our revenue opportunities into not only the CBD space but the mushroom space as...

Read more

RETRANSMISSION: Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

August 1, 2024 8:00 AM

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports, a Nature publication and the 5th most-cited journal in the world, according to the publisher. A link to the publication can be found HERE.JNJ-2113 is the first- and only-in-class targeted oral peptide inhibitor of the IL-23 receptor in clinical development. Based on...

Read more

FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug Candidate

August 1, 2024 7:45 AM

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work to ensure that any and all information contained within is true and accurate as of the date hereof to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.CHATHAM, NJ...

Read more

Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports

August 1, 2024 7:00 AM

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports, a Nature publication and the 5th most-cited journal in the world, according to the publisher. A link to the publication can be found HERE.JNJ-2113 is the first- and only-in-class targeted oral peptide inhibitor of the IL-23 receptor in clinical development. Based on...

Read more

OMS360 Appoints Dr. Joshua Everts as Chief Clinical Officer

August 1, 2024 7:00 AM

ATLANTA, GA / ACCESSWIRE / August 1, 2024 / OMS360 has appointed Joshua Everts, DDS, MD, a distinguished oral and maxillofacial surgeon, as the organization's first Chief Clinical Officer. In this new role, Dr. Everts will lead collaboration between surgeons, continuing education, and mentoring opportunities. He will also serve as the direct funnel of partner doctors' voices to champion clinical quality and effectiveness, advance a culture of...

Read more

Bausch Health Announces Second Quarter 2024 Results

August 1, 2024 7:00 AM

Second quarter consolidated revenues of $2.40 billion, up 11% on a Reported and 8% on an Organic (non-GAAP)1 basisConsolidated GAAP Net Income Attributable to Bausch Health Companies Inc. of $10 millionConsolidated Adjusted EBITDA Attributable to Bausch Health Companies Inc. (non-GAAP)1 of $798 million, up 10%Raising consolidated full-year Revenue and Adjusted EBITDA (non-GAAP)1 guidanceLAVAL, QC / ACCESSWIRE / August 1, 2024 / Bausch Health...

Read more

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

August 1, 2024 6:30 AM

SHELTON, CT / ACCESSWIRE / August 1, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports that two separate and independent research reports have been published by industry analysts on the Company."NNVC: NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy," is the title of a new research note published by David...

Read more

Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates

August 1, 2024 6:30 AM

CAMBRIDGE, MA / ACCESSWIRE / August 1, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2024."During the second quarter, we marked the approval of our second mRNA product and significantly lowered our operating costs. We remain focused on execution for the 2024-25 COVID season and the launch of our RSV vaccine in the U.S.," said Stéphane Bancel, Chief Executive Officer of...

Read more

Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET

August 1, 2024 6:30 AM

ANN ARBOR, MI / ACCESSWIRE / August 1, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, will host a conference call and audio-only webcast on Wednesday, August 14, 2024, at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its second quarter ended June 30, 2024. A...

Read more

MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory

August 1, 2024 5:20 AM

MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharmaceutical company in psychiatric medicine development, is pleased to report that it has appointed Haywood Securities Inc. ("Haywood") to act as strategic advisor to the Company to support its near-term objectives.Haywood's services will focus on assisting the Company to secure potential strategic level investment and transactions with strategic...

Read more

Syringe and Needle Industry in GCC Is Expected to Reach USD 1,164.90 Million by 2034 And Grow at A Compound Annual Growth Rate of 5.40% | Future Market Insights, Inc.

August 1, 2024 2:20 AM

The demand for syringes and needles in GCC countries is predicted to surge at a 5.40% CAGR through 2034. According to the estimates, the syringe and needle industry in GCC is valued at USD 688.5 million in 2024 and is projected to surpass USD 1,164.90 million by 2034.In the Gulf Cooperation Council (GCC) countries, the syringe and needle industry is undergoing shifts due to digital health technologies' introduction. Technological upgraded...

Read more

Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7, 2024

July 31, 2024 4:05 PM

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Second quarter of 2024 ended June 30, 2024, after the market closes on Wednesday, August 7, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To access the conference call, dial toll free 877-407-0989, for international calls, dial 201-389-0921, ten minutes before the conference.The call can also be...

Read more

The Siegel Rare Neuroimmune Association Kicks Off Awareness Campaign

July 31, 2024 2:00 PM

Campaign launched on the date organization president's wife developed symptoms of transverse myelitisPOWELL, OH / ACCESSWIRE / July 31, 2024 / Rare neuroimmune disorders can happen without warning and have devastating, lifelong effects. This was the case for Pauline Siegel. On July 31, 1994, she collapsed with intense pain in her lower back and soon was completely paralyzed below her waist. Pauline spent several days in the hospital and was...

Read more